Literature DB >> 18059026

Growth retardation and destruction of experimental squamous cell carcinoma by interstitial radioactive wires releasing diffusing alpha-emitting atoms.

Tomer Cooks1, Lior Arazi, Michael Schmidt, Gideon Marshak, Itzhak Kelson, Yona Keisari.   

Abstract

In the present study, we examined the antitumoral effects caused by the release of alpha emitting radioisotopes into solid squamous cell carcinoma (SCC) tumors. Using a novel method termed DART (Diffusing Alpha-emitters Radiation Therapy), we assessed the efficacy of short-lived daughters of (224)Ra releasing alpha particles, dispersing in the malignant tissue, to cause tumor growth retardation and destruction. It was carried out using specially designed wires loaded with (224)Ra activities in the range of 7-42 kBq in a set of experiments performed on BALB/c and nude mice bearing metastatic SCC tumors derived from either mouse SQ2 or human CAL27 cell lines. The insertion of a DART wire to the center of 6-7 mm primary tumors, retarded tumor growth, reduced lung metastatic load, prolonged life expectancy and in some cases caused tumor eradication. These effects were enhanced either when treating smaller tumors or treating identical tumors with 2 DART wires. Similar experiments on human-derived SCC tumors in nude mice were consistent with the outcomes of the murine model. Histological assessments revealed the tissue damage pattern, and indicated a role for the tumor vasculature in the dispersion of the atoms and the propagation of the damage. Our findings indicate that Diffusing Alpha-emitting Radiation Therapy is effective in a model system using SCC primary tumors. The in situ destruction of primary solid tumors by DART is evidently a necessary step toward curing cancer and might be augmented by chemotherapy and other modalities such as immunotherapy or antigrowth factors agents. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18059026     DOI: 10.1002/ijc.23268

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  6 in total

1.  Enhanced killing of cervical cancer cells by combinations of methyl jasmonate with cisplatin, X or alpha radiation.

Authors:  Elad Milrot; Anna Jackman; Eliezer Flescher; Pinhas Gonen; Itzhak Kelson; Yona Keisari; Levana Sherman
Journal:  Invest New Drugs       Date:  2012-09-06       Impact factor: 3.850

Review 2.  Radiotherapy Controversies and Prospective in Head and Neck Cancer: A Literature-Based Critical Review.

Authors:  Francesca De Felice; Antonella Polimeni; Valentino Valentini; Orlando Brugnoletti; Andrea Cassoni; Antonio Greco; Marco de Vincentiis; Vincenzo Tombolini
Journal:  Neoplasia       Date:  2018-02-12       Impact factor: 5.715

Review 3.  Atomic Nanogenerators in Targeted Alpha Therapies: Curie's Legacy in Modern Cancer Management.

Authors:  Mareike Roscher; Gábor Bakos; Martina Benešová
Journal:  Pharmaceuticals (Basel)       Date:  2020-04-23

4.  Clinical evidence of abscopal effect in cutaneous squamous cell carcinoma treated with diffusing alpha emitters radiation therapy: a case report.

Authors:  Salvatore Roberto Bellia; Giacomo Feliciani; Massimo Del Duca; Manuela Monti; Valentina Turri; Anna Sarnelli; Antonino Romeo; Itzhak Kelson; Yona Keisari; Aron Popovtzer; Toni Ibrahim; Giovanni Paganelli; Ignazio Stanganelli
Journal:  J Contemp Brachytherapy       Date:  2019-10-30

5.  Combining alpha radiation-based brachytherapy with immunomodulators promotes complete tumor regression in mice via tumor-specific long-term immune response.

Authors:  Vered Domankevich; Adi Cohen; Margalit Efrati; Michael Schmidt; Hans-Georg Rammensee; Sujit S Nair; Ashutosh Tewari; Itzhak Kelson; Yona Keisari
Journal:  Cancer Immunol Immunother       Date:  2019-10-22       Impact factor: 6.968

6.  Diffusing alpha-emitters radiation therapy in combination with temozolomide or bevacizumab in human glioblastoma multiforme xenografts.

Authors:  Yossi Nishri; Maayan Vatarescu; Ishai Luz; Lior Epstein; Mirta Dumančić; Sara Del Mare; Amit Shai; Michael Schmidt; Lisa Deutsch; Robert B Den; Itzhak Kelson; Yona Keisari; Lior Arazi; Tomer Cooks; Vered Domankevich
Journal:  Front Oncol       Date:  2022-09-27       Impact factor: 5.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.